| Biomarker ID | 137 |
| PMID | 17404077 |
| Year | 2007 |
| Biomarker | β-2-Microglobulin |
| Biomarker Basis | Concentration Based (μg/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Metastatic Prostate Cancer (Controls: 1.9± 0.6; Metastatic Castrate PCa: 2.7 ± 1.1) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- CTL mediated immune response against target cells,Nef-mediated downregulation of MHC class I complex cell surface expression,Nef in HIV-1 replication and disease pathogenesis, Ras-independent pathway in NK cell-mediated cytotoxicity,Antigen processing and presentation |
| Experiment | Controls Vs Metastatic Castrate Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Serum samples from 42 patients were collected from patients with prostate cancer and 14 controls. The sample set included patients with localized prostate cancer (n = 15), noncastrate metastatic (n = 5), castrate metastatic (immediately before cytotoxic chemotherapy; n = 17), and normal controls (n = 14) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | Serum from 14 unaffected individuals (siblings, children, or spouses of patients) was similarly collected to be used as controls. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | B2M |